Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences    GILD

GILEAD SCIENCES (GILD)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2018 01/12/2018 01/16/2018 01/17/2018 01/18/2018 Date
79.06(c) 79.02(c) 80.25(c) 81.74(c) 81.17(c) Last
7 872 939 6 366 180 11 750 181 11 162 836 8 527 500 Volume
+0.44% -0.05% +1.56% +1.86% -0.70% Change
More quotes
Financials ($)
Sales 2017 25 842 M
EBIT 2017 15 689 M
Net income 2017 10 478 M
Debt 2017 13 136 M
Yield 2017 2,60%
Sales 2018 22 094 M
EBIT 2018 12 454 M
Net income 2018 7 575 M
Debt 2018 10 119 M
Yield 2018 2,78%
P/E ratio 2017 10,53
P/E ratio 2018 14,19
EV / Sales2017 4,61x
EV / Sales2018 5,26x
Capitalization 106 B
More Financials
Company
Gilead Sciences, Inc. is a biopharmaceutical company, which discovers, develops and commercializes therapeutics for unmet medical need.It focuses on human immunodeficiency virus and liver diseases, such as chronic hepatitis C virus infection & chronic hepatitis B virus infection, hematology &... 
Sector
Biotechnology & Medical Research
Calendar
02/06 | 10:01pmEarnings Release
More about the company
Surperformance© ratings of Gilead Sciences
Trading Rating : Investor Rating :
More Ratings
Latest news on GILEAD SCIENCES
12:14p GILEAD SCIENCES : Findings from Gilead Sciences Yields New Findings on HIV/AIDS ..
11:17a GILEAD SCIENCES : Kite Announces Clinical Collaboration to Evaluate Investigatio..
01/18 GILEAD SCIENCES : Kite Announces Clinical Collaboration to Evaluate Investigatio..
01/13 GILEAD SCIENCES : GILD) Holder Continental Advisors LLC Lowered Holding as Share..
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
01/12 Respiratory Syncytial Virus Infections– Unmet Needs in Adult Targeted D..
01/08 $11 billion biotech binge fuels forecasts of 2018 M&A surge
01/07 Teen writes book about how to invest money Stock Whiz
01/04 GILEAD SCIENCES : Research Conducted at Gilead Sciences Has Provided New Informa..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/08 SANOFI : and Regeneron boost investment in cancer drug cemiplimab
More sector news : Bio Therapeutic Drugs
4-Traders Strategies on GILEAD SCIENCES 
GILEAD SCIENCES - 2014
A valuable trading opportunity
BUY
GILEAD SCIENCES - 2014
Continuation of the bullish trend
BUY
More Strategies
Latest Tweets
01:10pConfident Investor indicator analysis for 1/19/2018. Interesting results from.. 
12:27pGilead Sciences, Inc. $GILD Holdings Cut by Fayez Sarofim & Co.  
11:46aColumbia Partners L L C Investment Management Takes $241,000 Position in Gile.. 
12:36a$GILD ALERT: New Gilead Sciences SEC Filing From our Stock News Alerts App 
01/18#3 Insider trading scam spurred by $11.2B Gilead deal earns a stretch in pris..
7
More tweets
Qtime:369
News from SeekingAlpha
01/18 Biotech Forum Daily Digest For January 18th
01/18 ANALYZING THE CAR-T MARKET : What Companies Have Performed Best And Will The Tre..
01/18 YOUR DAILY PHARMA SCOOP : Juno Surges On Takeover Rumors, AEterna Zentaris Achie..
01/17 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : January 16, 2018
01/17 MERCK : Elucidating The Ramifications Of The Recent Keynote Findings
Chart GILEAD SCIENCES
Duration : Period :
Gilead Sciences Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Technical analysis trends GILEAD SCIENCES
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 86,5 $
Spread / Average Target 6,6%
EPS Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES14.10%106 002
REGENERON PHARMACEUTICALS-1.53%39 775
VERTEX PHARMACEUTICALS3.90%39 380
GENMAB12.29%11 532
EXELIXIS, INC.-2.47%8 772
BLUEBIRD BIO INC-8.28%7 486